# A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

> **NCT00321464** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 2049 (actual)

## Conditions studied

- Bone Metastases

## Interventions

- **BIOLOGICAL:** Denosumab
- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00321464
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-01
- **Primary completion:** 2009-07-20
- **Final completion:** 2012-04-04
- **Target enrollment:** 2049 (ACTUAL)
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321464, "A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00321464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*